

## **Colorectal cancer new: review ratio supporting document**

Currently the new: review ratio is set at 1:1.05 for general surgery however it is proposed that patients requiring colorectal cancer treatments are discounted from this calculation. The current pathway for patient's with colorectal cancer is attached to this document and details where consultant reviews are required.

This pathway is supported by guidance from the Northern Cancer Network which is also attached to this document. As the pathway details, the new:review ratio for colorectal cancer should be 1:3. 288 patients were admitted to this pathway in the last 12 months therefore it is recommended that these are taken out of the current statistics.

The need for follow is outlined within the NICE guidance attached to this document (page 21).